Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study
about
The Human Experience with Intravenous Levodopa17β-estradiol ameliorates light-induced retinal damage in Sprague-Dawley rats by reducing oxidative stressRisk of Parkinson's disease after tamoxifen treatment.Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's DiseaseFemale reproductive factors, menopausal hormone use, and Parkinson's disease.Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.Estrogen-related and other disease diagnoses preceding Parkinson's diseaseFormulations of hormone therapy and risk of Parkinson's disease.Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.Antioxidants as treatment for neurodegenerative disorders.Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studiesEstrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration.Chorea and contraceptives: case report with pet study and review of the literature.Hormone replacement therapy and risk for neurodegenerative diseases.Male/Female differences in neuroprotection and neuromodulation of brain dopamineQuinol-based cyclic antioxidant mechanism in estrogen neuroprotectionEstrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersOestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders.Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.The effect of estrogen in a man with Parkinson's disease and a review of its therapeutic potential.The relevance of gender in Parkinson's disease: a review.Increase of Reproductive Life Span Delays Age of Onset of Parkinson's Disease.Effects of chronic restraint stress and estradiol replacement on glutamate release and uptake in the spinal cord from ovariectomized female rats.Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia.Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan.Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.Differential effects of age on human striatal adenosine A₁ and A(2A) receptors.The effects of estradiol on estrogen receptor and glutamate transporter expression in organotypic hippocampal cultures exposed to oxygen--glucose deprivation.Review of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potentialGender differences in Parkinson's disease
P2860
Q26771516-22379F45-5D8D-4F47-88F6-A0F04CDDA244Q28573578-56995A92-7D5F-472A-8A09-8E2F03ABB04AQ33552831-7593A346-C478-4C8F-BB41-072C131AC0F8Q33740654-3097F2F8-BD9F-477E-ABB5-35ECFCB927A6Q33756791-EA605709-9A8A-4C41-AB1B-4D76CB14DCACQ33874635-8C0E93DD-0075-4661-8681-0C76207A39B5Q34144121-2A9824BA-074A-4CDD-AE4B-3E86E0335CE7Q34437648-299282F2-2E91-40EA-BF79-5DA5E8A68F97Q34523361-FD94CFFC-0CDB-45D4-83B7-1A0EAD5110E7Q34974866-D1A48B66-C9F3-4AE3-A35A-3124FD570AD9Q35049313-E0E121B6-B488-4CA1-B6DA-2685FFEF3E61Q35230714-A7CBF3EE-4323-43CD-97F6-9FE9DB43CC0EQ35691631-B87D7010-B65B-49E3-BCB3-4E075341963FQ35884815-923173C4-D0B0-4284-8FDE-BE2CBB7CF093Q35972056-7E044722-1494-4556-8999-B0F8DD0DF13AQ36161592-488DF687-64FB-4386-805E-5B20121CBD84Q36763772-CAEBD8C0-118E-48EC-9BFB-B0CC15875384Q36799584-BF027865-14CD-4B01-977C-EFE29A0226A0Q36854132-0FD8798A-165C-4232-8701-DF30AD6109EFQ37765941-73234D2B-92FB-41DE-A337-5F3EE26247F7Q37905899-490A7392-EA57-48E2-BC9A-D56F1D8119DEQ38102751-A2512F1B-AA0B-421D-8E93-C92CBE443F86Q39039214-D8B7861E-A2E2-44EE-8E69-0572540489A8Q46027706-2F17A3E3-160A-45E1-95A0-66B913C94D5FQ46422814-32D17379-4FA9-4D4B-ABF6-0105EDEFB80EQ46596326-5F35B3DA-4848-4EF3-842E-9714C9227EB9Q46597362-E8EB7EE8-AF0B-46B3-BBA8-996DACF8B10AQ47623516-AB594AAB-4377-491A-AC12-A62E469486E2Q48473102-51C25269-6DE7-4171-AC08-FDCA352705C8Q48496249-84FB3B0C-976B-48A8-9B99-D18D43B80FCBQ48507601-EECA6D92-AFA9-4E90-BAC4-6286F9D5A73BQ56031122-65BF41D3-BFF9-4CD6-93FE-AFFF65883C43Q57779630-DFA4089D-2CE1-45EF-BDC1-999F81D26504
P2860
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Short-term effects of high-dos ...... PD patients: a crossover study
@ast
Short-term effects of high-dos ...... PD patients: a crossover study
@en
Short-term effects of high-dos ...... PD patients: a crossover study
@nl
type
label
Short-term effects of high-dos ...... PD patients: a crossover study
@ast
Short-term effects of high-dos ...... PD patients: a crossover study
@en
Short-term effects of high-dos ...... PD patients: a crossover study
@nl
altLabel
Short-term effects of high-dos ...... PD patients: A crossover study
@en
prefLabel
Short-term effects of high-dos ...... PD patients: a crossover study
@ast
Short-term effects of high-dos ...... PD patients: a crossover study
@en
Short-term effects of high-dos ...... PD patients: a crossover study
@nl
P2093
P356
P1433
P1476
Short-term effects of high-dos ...... PD patients: a crossover study
@en
P2093
P356
10.1212/WNL.53.1.91
P407
P577
1999-07-13T00:00:00Z